A blockade of landmark immune checkpoints expressed on immune and cancer cells, namely the cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death (PD) 1 (PD-1), and the ligand of the latter (PD-L1), harnesses the immune system to attack cancer cells [2,3]. The gene discussed is CTLA4; the disease is cancer.